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INTRODUCTION:
MicroRNAs (miRNAs) are described as non-coding
ribonucleic acids with 18-22 nucleotide bases. Expression
of miRNAscan be transformed in breast cancer when
compared to healthy breast tissue.There may also be
difference in expression in breast cancer subtypes. Their
mode of action maybe as either oncogene or tumor
suppressors; this shows that their expression is
deregulated in cancers. MicroRNAs are also used during
development stages and have been found to be involved
in processes such as proliferation, differentiation and
apoptosis. Breast cancers are controlled by cancer-
restricted signaling pathways.1Methods to diagnose
breast cancer are many, the most common being
mammography which is utilized for screening and
diagnosing purposes. But scanning is not the gold
standard for diagnosis as confirmation of cancers is by
means of biopsy which is an invasive procedure. This
procedure is performed when the patient complains of
lumps in the mammary gland.1,2 Breast Cancer originates
at cellular level but diagnosis can only take place once
the signs and symptoms appear. Multiple genetic based
procedures have been determined to mark the genetic
signatures causing this cancer.In comparison to other
continents, Asia has the highest rates of breast cancer;
it is considered as the most frequently occurring cancer
of origin in women in this region. Pakistan’s leading
cancer to date in women is also breast cancer.2,3 Till to
date no robust and precise method has been determined
to predict the occurrence of this deadly disease. Hence
there is a need to identify sensitive biomarkers that will
be beneficial for discovering breast cancers and
differentiate between aggressive versus non-aggressive
tumors.4,5,6 The association of manifold miRNAs with
breast cancer is becoming a promising method for
diagnosing this cancer at cellular level which may lead
to diminishing prevalence of the disease. Therefore there
is a dire need to identify miRNA and label them as
diagnostic factors. They may also be useful in prognosis
of the disease, as well as possible remedy targets.7, 8, 9
Literature search was performed by using database of
PubMed. The keywords used were microRNA (52
searches) and breast cancer (169 searches). PERN was
used by database of Bahria University. This included
literature and articles from international sources; local
literature on this topic was not available. Out of these,
35 articles were shortlisted which discussed relation of
microRNA genetic expression in breast cancer. These
articles were consulted for this review.
LIEERATURE REVIEW:
MicroRNAs (miRNAs) are RNAs of 18-22 nucleotides
(nt) in extent which are found profusely in plants, animals
and also viruses.These small genes are formed by a
sequence of events first in the nucleus and then in the
cytoplasm. In the nucleus they are originally transcribed
as primary-mi-RNA (pri-miRNA) due to the presence
of RNase polymerase II which is 100-1000 nucleotide
in length. This is followed by the process of capping
and polyadenylation. Further this pri-miRNA is cut by
RNase III, DROSHA and its co-factor DGCR8 into
smaller70 nucleotide stem loops called as pre-RNA.7,8
This pre-RNA journey`s from nucleus to cytoplasm by
means of exportin-5. The loop region of pre-RNA is
removed by DICER (RNase III) and its binding partner
TRBP. A mature miRNA-miRNA* duplex is released.
9 The single dominant strand is incorporated with RISC
(RNA induced silencing complex) to finally regulate
gene expression by complementary-base pair interaction
resulting in interference with translational ability and
stability of target mRNA or it may result in its
degradation.10,11 Multiple miRNAsare linked with breast
cancer and it is a fact now that most of these post
transcript structures may transform complex functional
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ABSTRACT:
Breast Cancer is the commonest cancer affecting women worldwide especially in Asia. Several proteinaceous,genetic and
epigenetic biomarkers areallied with the disease but their efficacy as vigorous and robust indicators of disease remains uncertain.
The need to detectand differentiate aggressive from non-aggressive breast tumors at cellular level is being investigated.
MicroRNAs seem to be a promising marker to identify the disease before it reaches aggressive level. MicroRNAs (miRNAs)
are small 18-24 nucleotide RNAs which regulate the expression of approximately 30% of human genes. Their expression is
frequently deregulated in cancers. .miRNAshave been found in significantly large copy numbers in serum/plasma of cancer
patients. The stability of the serum miRNAs is not compromised even if the samples are treated with RNase or incubated at
room temperature over prolong periods or subjected to repeated freeze-thaw cycles. miRNAs that are breast cancer-specific
can therefore be employed as disease predicting biomarkers.
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networks of mRNAs. Diagnostic tools are available but
more genetic markers which would allow the prevention
of the disease are required. This is where the importance
of identifying miRNAs as potential biomarkers is of
great importance to scientists.An additional advantage
related tomiRNAs in oncology is that they are remarkably
stable and are notably detectable in serum and plasma.
Triple negative breast cancer which is aggressive in
nature shows strong linkage to various miRNAs. Five
microRNA (miRNA)clusters which include miR-17-92
at 13q 31.3, miR-183-182 at 7q32.2, miR-200-429 at
1p 36.33, miR-301b-130b at 22q 11.21, and miR-532-
502 at xp 11.23 were upregulated in triple negative
breast cancer. This research is a promising research in
clearly identifying global miRNAs regulatory
characteristics in ER–ve, PR-ve and HER2 –ve breast
cancer.3Studies related to gene expression have proven
that estrogen and progesterone receptors (positive/-
negative) are expressed as distinct disease at molecular
level. Human epidermal growth factor receptor 2(HER2)
if tested significantly affirmative promotes the growth
of cancer cells and is normally involved in functions
such as signal transduction pathways influencing cell
growth and differentiation.4 Huang GI et al has reported
that ER/ PR negative cancers show high expression of
miR-21. ER, PR and HER2 negative (triple negative
tissue) have exhibited very high expression of some
miRNAs e.g. miR-21, miR-155, miR-145, miR-16.5
This finding is consistence with several other reports
indicating the aggressive nature of tumor with negative
receptor proteins. Metastasis of cancer is also linked to
triple negative tumors and have poor prognosis and do
not respond properly to chemotherapy. Several current
studies have shown the importance of detecting blood
based miRNAs in breast cancer and this has revealed
new biomarkers. A pilot study shows that the presence
of urinary miRNAs may also be used to diagnose breast
cancer. It was shown that urinary miR-155 levels were
significantly higher in breast cancer patients as compared
to healthy controls. This urinary miRNA was quantified
by real time PCR.6
A greater proportion of miRNAs which are around 600
in number, have been identified already which participate
in development as well as regulate developmental
sequences in a growing fetus.12,13,14 This includes
mechanism such as increase in the cell number of organs,
their differentiations to form body structures and these
genes may also control the process of apoptosis and
cellular metabolism.15 A substantial number of genes
and their expression are controlled by miRNAs impact.
It is likely that any changes in their expression or DNA
sequence are likely to culminate in a diseased state. A
study on Hispanic women showed a different pattern in
women after pregnancy who are diagnosed with breast
cancer in less than 5 year of pregnancy. This postpartum
development of breast cancer showed two-fold or higher
difference in expression with miR-138, miR-660, miR-
31, miR-135b, miR-135b, miR-17, miR-454 and miR-
934 being overexpressed. This study forecasts that
miRNAs may have different pattern depending upon
the ethnicity and condition of women.15, 16 The miRNomes
of several cancers have been studied and such studies
have identified miRNAs whose expression levels are
robustly compromised. In biopsies obtained from breast
cancer patients such miRNA profiling exercise revealed
29 miRNAs whose expression was down-regulated in
tumors.1 A recent study revealed specific miRNA
signatures that were unique for several benign and
malignant tumors, some of the common organs include
the breast, prostrate, lung and the intestines. In advanced
breast cancer, metastasis to the brain is a cause of death
in such patients. The phenomena behind this is that
cancer cells migrate through blood brain barrier, however
the molecular mechanism still remains to be investigated.
It has been shown that the delivery of these cancer cells
maybe via miRNAs which maybe involved in the
breakdown of the blood brain barrier. The identified
miRNA which may promote this event is miRNA-
181c.This identified miRNA causes destruction of blood
brain barrier through abnormal localization acting via
down regulations of its target gene PDPK1.17, 18 Some
of the highly expressed miRNAs that were found in this
study were miRNAs 155, 17-5p, 20a, 21, 92, and 106a.
Functional genomic validation of some of the miRNAs
identified through the gene array screens proved that
miRNAshave a definite action as oncogenes or
suppressor genes implying that any mutations or un-
programmed changes in their expression levels has the
potential to trigger uncontrolled cellular proliferation
miRNAs that are metastasis promoters as well as
suppressors have also been identified.19, 20 In this
decade several studies carried out on cell lines derived
from breast cancers as well on primary tumors have
been performed in an effort to identify miRNAs which
are unique to these types of cancers and which are
abnormally expressed. Profiles obtained from 76 breast
cancer tissues which were primary in nature as compared
to 34 non malignant counterparts led to the identification
of 5 different miRNAs ,that were deregulated. Among
the given cases 3 showed that miR-10b,-125b, and 145
were most significantly down-regulated. In addition
2miRNAs were found to be up-regulated (miR21, and
miR155).1 In another study, miRNA profiles were
obtained from primary breast cancers, in which 5were
normal breast samples and 21 samples included breast
cancer tissue cell lines.On further experimentation of
these samples derived from breast  cancer
individuals,exposed conspicuous variances in miRNA
expression when ER-ve and ER+ve tumors were studied.
The investigators also showed that they were able to
discriminate between HER2+ and HER2– cancers based
on miRNA signature.3
Recently, Literature search revealed that Mitchell et al
has studied the presence of miRNA in human plasma
which are unusually stable culminating to the fact that
they are able to resist degradation even if exposed to
freeze thaw cycles repeatedly. These micro genes also
have the capability tosurvive prolonged incubations at
room temperature. This experiment demonstrated
that miRNAs are secure from endogenous RNase
performance in the plasma of human beings thus prposing
that they may be considered as a portion of complexes
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or may be associated with exosomal vesicles. Although
inconclusive, this study also found that mir-141 can
serve as a biomarker.21
Studies related to gene expression have proven that
estrogen and progesterone receptors (positive/negative)
are expressed as distinct disease at molecular level.
Human epidermal growth factor receptor 2(HER2) if
shown to be present promotes the growth of cancer cells
and is normally involved in functions such as signal
transduction pathways influencing cell growth and
differentiation. Correlation between clinico-pathological
factors and miRNAs concentration is very important
especially for treatment purposes. Multi variant analysis
of breast cancer in various stages show very high
concentration of some circulating miRNAs but this may
be independent of ER, PR and HER2. Henegham
reportednumber of miR-21 in a greater quantity in the
circulation in ER negative disease as compared to those
individuals whose biopsy showed ER positive breast
cancer.22 They also tried to establish a relationship
between this circulating gene, type of breast cancer
which maybe of in situ type but may also be invasive,
the subtype and HER2 status but no significant relation
could be established.2
In a study on Asian Indians and Pakistani, the receptor
status in relation to age was analyzed showing that in
ages between 40-50 years an increased percentage of
ER/PR negative disease was noted as compared to the
younger group. However over time pathologically
assessed cancers show that triple negative receptors are
more common in this part of the world which may result
in recurrences, resistance to treatment and metastasis
in brain and spinal cord.21,23
Pakistan presently is considered to have the uppermost
rates of breast cancer in Asia; it has also been proved
that breast cancer is the most common cancer among
other gynecological cancers. India and Pakistan have
reported a significant rise in the incidence of breast
cancer. ER, PR negative breast cancer are more common
according to several reported studies.2 In a tertiary cancer
care hospital in Karachi, a study of over a span of nine
yearswas conducted which showed that breast cancer
was the most frequently occurring cancerin females and
consisted of 38.2% of the entirecancer cases inducted
in that institution, this was proved to be highest in Asia.23
For breast cancer treatment to be attainable we must
first identify biomarkers which will robustly reduce
universal morbidity and mortality due to this disease.
Research also shows that there is a difference in the
expression of miRNAs in various diseases. There is
indication that there may also be different expression
in various populations. Hence the importance of
identifying these micro genes in a sample of Pakistani
population will be of benefit as we will be able to
differentiate it with the western data. 16 This will however
be possible with larger sample size studies with
participants from all parts of the country. Smaller studies
should also be conducted as they may provide cues for
further studies.Therefore identification and the quantity
of tumor-derived miRNAs in the circulation are an
essential methodology for blood based exposure of
human cancer which will lead to (1)diagnosis and (2)
prognosis of cancer by non-invasive methods and will
(3) determine their relation with protein receptors in
tissue biopsy of breast cancer and level of aggressiveness
of the breast tumor.24, 25
As developing confirmations highlight the significance
of miRNAs in diagnosis and prognosis, the usefulness
of miRNAs based breast cancer therapy is also being
explored. Many miRNAs have been associated in
numerous cancers, including breast cancer. They are
known to control cell cycle and developmental processes.
Therefore it is likely that miRNAs are beneficial targets
for exploring in anti-cancer treatments.25,26 The therapeutic
strategies based on miRNAs suggest a substitute for
targeting multiple gene networks that are controlled by
a single miRNA. These approaches can be expressed
by either antagonizing or reinstating the functions of
miRNAs27,28,29 Anti-miRNA 2-O-methyl or blocked
nucleic acid oligonucleotides used to inactivate
oncomiRNAs such as miR-21 in breast cancers may
taper down tumor growth. Anti-miR-21induced decrease
in cancer growth was revealed to be potentiated by the
addition of topotecan (a chemotherapeutic agent), this
is an inhibitor of DNA topoisomerase I.29,30,31 Such novel
event highly recommends that suppression of the
oncogenic miR-21 could sensitize tumor cells to anti-
cancer therapy.This is a promising prospect for patients
displaying a poor response to initial stages of
chemotherapy.32,33,34,35 Another point of interest shows
the capability of miRNA 34a to inhibit proliferation and
migration of breast cancer through down regulation of
Bcl-2 and SIRT136,37,38,39,40
CONCLUSION:
It is important to check the contributory factors (genetic
and non-genetic) since incidence rates are on such a
rapid rise. As with many cancers, early detection of
breast cancers has been inadequate and methods for
prognosis and diagnosing the disease are limited to
invasive procedures. Due to advances in understanding
the cancer cell at molecular level, development of several
targeted therapies are progressing and have also lead to
advancement in the treatment. To achieve such
individualized treatment appropriate targets must be
identified.
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